New AI matchmaker pairs ALS patients with clinical trials in seconds
EverythingALS reports 92% success rate in identifying eligible research studies
Written by |
- EverythingALS launched SAVA AI, an online tool for ALS patients.
- It uses AI to instantly match patients to relevant clinical trials.
- This tool helps overcome diagnostic delays and short enrollment windows.
EverythingALS has launched a new online tool called SAVA AI that uses artificial intelligence to instantly match people with amyotrophic lateral sclerosis (ALS) to clinical trials.
The platform is available for free through the EverythingALS website or as a mobile app, providing patients with a secure way to find research opportunities they may be eligible for in real time.
By entering their health information into the tool, users receive immediate alerts about relevant studies and can share those findings with their doctors and families. This digital resource aims to remove the guesswork from finding experimental treatments, ensuring that a patient’s location or personal connections do not limit their access to care.
“We created SAVA AI because access to clinical trials should never depend on chance, geography, or connections,” Indu Navar, founder and CEO of EverythingALS, said in a press release. “By harnessing AI and citizen-driven research, we’re giving patients the power to find opportunities that could change the course of their own disease journey, and accelerating the entire community’s path toward a cure.”
Navigating the challenges of clinical trial enrollment
After an ALS diagnosis, finding clinical trial opportunities quickly is often a vital part of a patient’s care plan. While currently approved treatments can help manage symptoms or slightly slow the progression of the disease, their impact is often limited. This leads many patients to seek out clinical trials to access experimental therapies and contribute to the search for a cure.
However, timing is one of the biggest hurdles in this process. Many clinical studies only accept participants who are within the first two years of their symptom onset. Because diagnostic delays often mean patients wait 10 to 16 months for a formal diagnosis, the window to enroll in a study is frequently very short.
In addition to these time constraints, both patients and doctors may struggle to stay informed about every available study. It can be difficult to manually filter through hundreds of trials to find the ones that match a person’s specific health profile.
SAVA AI is designed to make this process much more efficient. The platform analyzes a patient’s health data and compares it against the eligibility requirements of current studies to find potential matches. It also alerts users to options like genetic testing and sends notifications the moment a new, relevant trial opens up.
The tool uses a conversational interface that asks users questions about their clinical assessments, when their symptoms first began, their location, and what they prefer in a trial. It then pulls tailored information from verified sources like ClinicalTrials.gov. The system can also answer specific questions, such as whether a certain trial is available in a specific state.
According to a news story by Navar, the platform combines large-language-model technology with curated clinical data. The system is continuously updated based on feedback from patients, researchers, and clinicians to ensure it remains helpful and accurate. To protect user privacy, the AI only uses data and insights from EverythingALS.
The organization reports that the tool can connect patients to the right trials in seconds. So far, it has achieved a 92% accuracy rate in identifying studies that align with a patient’s specific eligibility criteria.
Leave a comment
Fill in the required fields to post. Your email address will not be published.